Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Free Cash Flow over the past 12 years, most recently at -$24.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$24.0 million for Q4 2025, up 67.33% from a year ago — trailing twelve months through Dec 2025 was -$276.9 million (down 18.92% YoY), and the annual figure for FY2025 was -$276.9 million, down 18.92%.
  • Free Cash Flow for Q4 2025 was -$24.0 million at Viridian Therapeutics, Inc.\DE, up from -$84.7 million in the prior quarter.
  • Over the last five years, Free Cash Flow for VRDN hit a ceiling of -$11.5 million in Q1 2021 and a floor of -$92.7 million in Q1 2025.
  • Median Free Cash Flow over the past 5 years was -$38.8 million (2023), compared with a mean of -$42.2 million.
  • Biggest five-year swings in Free Cash Flow: crashed 193.38% in 2023 and later surged 67.33% in 2025.
  • Viridian Therapeutics, Inc.\DE's Free Cash Flow stood at -$16.6 million in 2021, then plummeted by 106.23% to -$34.3 million in 2022, then fell by 13.42% to -$38.9 million in 2023, then tumbled by 88.94% to -$73.4 million in 2024, then surged by 67.33% to -$24.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$24.0 million (Q4 2025), -$84.7 million (Q3 2025), and -$75.4 million (Q2 2025) per Business Quant data.